Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.

about

Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q39576908

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Financial consequences of a pa ...... ve non-small-cell lung cancer.

@en

Financial consequences of a pa ...... ve non-small-cell lung cancer.

@nl

type

Item

label

Financial consequences of a pa ...... ve non-small-cell lung cancer.

@en

Financial consequences of a pa ...... ve non-small-cell lung cancer.

@nl

prefLabel

Financial consequences of a pa ...... ve non-small-cell lung cancer.

@en

Financial consequences of a pa ...... ve non-small-cell lung cancer.

@nl

P1476

Financial consequences of a pa ...... ve non-small-cell lung cancer.

@en

P2093

Ana Clopes

http://www.w3.org/2001/XMLSchema#string

Antoni Gilabert

http://www.w3.org/2001/XMLSchema#string

Candela Calle

http://www.w3.org/2001/XMLSchema#string

Josep R Germà

http://www.w3.org/2001/XMLSchema#string

Luis A Cordero

http://www.w3.org/2001/XMLSchema#string

Luis Segú

http://www.w3.org/2001/XMLSchema#string

Montse Gasol

http://www.w3.org/2001/XMLSchema#string

Ramón Mora

http://www.w3.org/2001/XMLSchema#string

Ricard Crespo

http://www.w3.org/2001/XMLSchema#string

Rosana Cajal

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13696998.2016.1215991

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27441909

http://www.w3.org/2001/XMLSchema#string